ESSA Pharma saw the highest growth of 0.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of ESSA Pharma’s patent filings and grants. Buy the databook here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
ESSA Pharma has been focused on protecting inventions in European Patent Office(EPO) with one publication in Q2 2024
The South Korea(KR), United States(US), and European Patent Office(EPO) patent Office are among the top ten patent offices where ESSA Pharma is filings its patents..
Roche and Johnson & Johnson could be the strongest competitors for ESSA Pharma
Patents related to rare diseases lead ESSA Pharma's portfolio
ESSA Pharma has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Prostate cancer related patents lead ESSA Pharma portfolio followed by metastatic prostate cancer, and hormone-sensitive prostate cancer
ESSA Pharma has highest number of patents in prostate cancer followed by metastatic prostate cancer, hormone-sensitive prostate cancer, breast cancer, and hepatocellular carcinoma.
For comprehensive analysis of ESSA Pharma's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

